Individuals with underlying heart disease may want to avoid energy drinks going forward, according to a new Mayo Clinic analysis.

Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.

Veteran cardiologist Harlan M. Krumholz, MD, has a long history in medical research as both an author and an editor. He and his team want to review manuscripts quickly and publish a wide variety of voices.

Based on positive results from two different trials, Eli Lilly and Company hopes to secure a new FDA approval for tirzepatide in the months ahead.

The newly approved DeepRhythm Platform from Medicalgorithmics uses advanced AI to evaluate imaging results and look for signs of cardiac arrhythmias.

The Cordella platform from Endotronix includes an implantable sensor that tracks the patient’s PA pressure and other helpful health data.

“Understanding the sex differences in obesity-related HFpEF is of great importance,” one cardiologist explained. “Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women."

Interventional cardiologist Peter Monteleone, MD, discussed the primary tools used to treat pulmonary embolism in the cath lab.

The new-look diet was linked to significant weight loss and reductions in HbA1C levels. Researchers see it as a potential alternative to immediately putting patients on new medications. 

A majority of U.S. surgeons, including those who treat heart patients on a daily basis, say their operating rooms use outdated technology. It is having a negative impact on patient care.